Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Фемара (летрозол) в современной терапии рака молочной железы
Фемара (летрозол) в современной терапии рака молочной железы
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Geisler J, Haynes B, Anker G et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized cross-over study. J Clin Oncol 2002; 20: 751–7.
2. Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer (abstr.). J Clin Oncol 2006; 24 (suppl. 18): 552.
3. Gershanovich M, Chaudi HQ, Campos D et al. for the Letrozole International Trial Group (AR/BC3) Letrozole, a new oral aromatase inhibitor; randomized trial comparing 2,5 mg dayly, 0,5 mg dayly and aminogluthetimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998; 9: 639–45.
4. Buzdar A, Douma J, Davidson N et al. Phase III multicenter, double-blind, randomized study of letrozole an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 17: 3357–66.
5. Dombernowsky P, Smith I, Falkson J et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453–61.
6. Rose C, Vtoraya O, Pluzanska A et al. An open randomized trial of second-line endocrine tsapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Brit J Cancer 2003; 39: 2318–27.
7. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tampoxifen as first-line therapy in advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Breast Cancer Group. J Clin Oncol 2003; 21: 2101–9.
8. Mouridsen H. Letrozole in advanced breast cancer. Breast Cancer Res Treat 2007; 105: 19–29.
9. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 2007; 105: 33–43.
10. Eierman W, Paepke S, Apfelsteadt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12 (11): 1527–32.
11. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687–717.
12. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxofen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684–90.
13. Koeberle D, Thuerlimann B. Letrozole as upfront therapy for postmenopausal women with hormone-sensitive breast cancer BIG 1-98. Breast Cancer Res Treatm 2007; 105: 55–66.
14. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozol in postmenopausal women after five years of tamoxifen therapy for early breast cancer. N Engl J Med 2003; 349: 1793–802.
15. Goss PE, Ingle JN, Martino S et al. Randomized trial of Letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: updated findings from NCIC CTO MA.17. J Nat Cancer Inst 2005; 97: 1262–71.
16. Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treatm 2007; 105: 45–53.
17. Ingl JN, Tu D, Pater JL et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008; 19: 877–82.
18. Bundred N, Campbell I, Davidson N et al. Effective inhibition of aromataze inhibition-associated bone loss by Zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. ZOFAST study results. Cancer 2008; 112: 1001–10.
19. Bertelli G, Garrone O, Merlano M et al. Sequential treatment with Exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69: 471–7.
20. Dowsett M. Factors predicting response and resistance to endocrine therapy of breast cancer. ASCO Educational Book, 2008; 14–7.
21. Aebi S, Rabaglio M. Overview of current approaches to adjuvant endocrine therapy. ASCO Educational Book, 2008; 9–13.
2. Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer (abstr.). J Clin Oncol 2006; 24 (suppl. 18): 552.
3. Gershanovich M, Chaudi HQ, Campos D et al. for the Letrozole International Trial Group (AR/BC3) Letrozole, a new oral aromatase inhibitor; randomized trial comparing 2,5 mg dayly, 0,5 mg dayly and aminogluthetimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998; 9: 639–45.
4. Buzdar A, Douma J, Davidson N et al. Phase III multicenter, double-blind, randomized study of letrozole an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 17: 3357–66.
5. Dombernowsky P, Smith I, Falkson J et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453–61.
6. Rose C, Vtoraya O, Pluzanska A et al. An open randomized trial of second-line endocrine tsapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Brit J Cancer 2003; 39: 2318–27.
7. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tampoxifen as first-line therapy in advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Breast Cancer Group. J Clin Oncol 2003; 21: 2101–9.
8. Mouridsen H. Letrozole in advanced breast cancer. Breast Cancer Res Treat 2007; 105: 19–29.
9. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 2007; 105: 33–43.
10. Eierman W, Paepke S, Apfelsteadt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12 (11): 1527–32.
11. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687–717.
12. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxofen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684–90.
13. Koeberle D, Thuerlimann B. Letrozole as upfront therapy for postmenopausal women with hormone-sensitive breast cancer BIG 1-98. Breast Cancer Res Treatm 2007; 105: 55–66.
14. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozol in postmenopausal women after five years of tamoxifen therapy for early breast cancer. N Engl J Med 2003; 349: 1793–802.
15. Goss PE, Ingle JN, Martino S et al. Randomized trial of Letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: updated findings from NCIC CTO MA.17. J Nat Cancer Inst 2005; 97: 1262–71.
16. Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treatm 2007; 105: 45–53.
17. Ingl JN, Tu D, Pater JL et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008; 19: 877–82.
18. Bundred N, Campbell I, Davidson N et al. Effective inhibition of aromataze inhibition-associated bone loss by Zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. ZOFAST study results. Cancer 2008; 112: 1001–10.
19. Bertelli G, Garrone O, Merlano M et al. Sequential treatment with Exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69: 471–7.
20. Dowsett M. Factors predicting response and resistance to endocrine therapy of breast cancer. ASCO Educational Book, 2008; 14–7.
21. Aebi S, Rabaglio M. Overview of current approaches to adjuvant endocrine therapy. ASCO Educational Book, 2008; 9–13.
Авторы
Н.И.Переводчикова
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.